跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLN-POSACONAZOLE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
GLN-POSACONAZOLE
Authorized
STANDARD
GLN-POSACONAZOLE
glenmark pharmaceuticals canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ae6b89f146afe3d0
Company
glenmark pharmaceuticals canada inc.
Type
Standard
Approval Details
Approval Id
ae6b89f146afe3d0
Drug Approval Canada Name
GLN-POSACONAZOLE
Product Name
GLN-POSACONAZOLE
Status
Marketed
Status Date
2023-10-04
Original Market Date
2023-10-04
Din
02542021
Drug Class
Human
Dosage Form
Tablet (Delayed-Release)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:14.08
Atc Original
J02AC04 POSACONAZOLE
Atc Name
j 02 ac 04
Aig Number
0152201002
Company Name
glenmark pharmaceuticals canada inc.
Company Address
1600 Steeles Ave. W., Suite 407, Concord, Ontario, Canada, L4K 4M2
Active Ingredients
POSACONAZOLE
100 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ae6b89f146afe3d0
Type
Standard
Back to Health Canada Approvals